Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease

Progress in Neurobiology

Volumn 81, Issue 5-6, 2007, Pages 331-348

  Popoli, Patrizia ^a   Blum, David ^b,c   Martire, Alberto ^a   Ledent, Catherine ^d   Ceruti, Stefania ^e   Abbracchio, Maria P ^e  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^c UNIV LILLE   (France)

^d UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Adenosine A2A receptors; Huntington's disease; Neurodegenerative mechanisms; Neuroprotection

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 3 HYDROXYPROPYL 8 (3 METHOXYSTYRYL) 7 METHYL 1 PROPARGYLXANTHINE; 3,7 DIMETHYL 1 PROPARGYLXANTHINE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMIC ACID; ISTRADEFYLLINE; K 252A; METHYLXANTHINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; QUINOLINIC ACID; UNCLASSIFIED DRUG; V 2006; XANTHINE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; CELL POPULATION; CLINICAL TRIAL; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG ACTIVITY; DRUG MECHANISM; GLIA CELL; HOMEOSTASIS; HUMAN; HUNTINGTON CHOREA; MITOCHONDRIAL TOXICITY; NERVE CELL NECROSIS; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; REVIEW;

EID: 34047161070     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2006.12.005     Document Type: Review

References (173)

1. Abbracchio M.P., Colombo F., Di Luca M., Zaratin P., and Cattabeni F. Adenosine modulates the dopaminergic function in then nigro-striatal system by interacting with striatal dopamine dependent adenylate cyclase. Pharmacol. Res. Commun. 19 (1987) 275-286
2. 3 receptors in rat brain. Mol. Pharmacol. 48 (1995) 1038-1045
3. 3 receptors and viability of astrocytes. Drug Dev. Res. 45 (1998) 379-386
4. Alexi T., Borlongan C.V., Faull R.L., Williams C.E., Clark R.G., Gluckman P.D., and Hughes P.E. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases. Prog. Neurobiol. 60 (2000) 409-470
5. Alfinito P.D., Wang S.P., Manzino L., Rijhsinghani S., Zeevalk G.D., and Sonsalla P.K. Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. J. Neurosci. 23 (2003) 10982-10987
6. Altar C.A., Cai N., Bliven T., Juhasz M., Conner J.M., Achenson A.L., Lindsay R.M., and Wiegand S.J. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 389 (1997) 856-860
7. Arrasate M., Mitra S., Schweitzer E.S., Segal M.R., and Finkbeiner S. Inclusion body formation reduces levels of mutant Huntingtin and the risk of neuronal death. Nature 431 (2004) 805-810
8. Bantubungi K., Jacquard C., Greco A., Pintor A., Chtarto A., Tai K., Galas M.C., Tenenbaum L., Deglon N., Popoli P., Minghetti L., Brouillet E., Brotchi J., Levivier M., Schiffmann S.N., and Blum D. Minocycline in phenotypic models of Huntington's disease. Neurobiol. Dis. 18 (2005) 206-217
9. 2A adenosine receptor antagonists. J. Med. Chem. 41 (1998) 2126-2133
10. Beal M.F. Role of excitotoxicity in human neurological disease. Curr. Opin. Neurobiol. 2 (1992) 657-662
11. Beal M.F., and Ferrante R.J. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat. Rev. Neurosci. 5 (2004) 373-384
12. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J., and Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321 (1986) 168-171
13. Beal M.F., Ferrante R.J., Swartz K.J., and Kowall N.W. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci. 11 (1991) 1649-1659
14. Beal M.F., Brouillet E., Jenkins B., Henshaw R., Rosen B., and Hyman B.T. Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J. Neurochem. 61 (1993) 1147-1150
15. Behrens P.F., Franz P., Woodman B., Lindenberg K.S., and Landwehrmeyer G.B. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain 125 (2002) 1908-1922
16. Bemelmans A.P., Horellou P., Pradier L., Brunet I., Colin P., and Mallet J. Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. Hum. Gene Ther. 10 (1999) 2987-2997
17. Benchoua A., Trioulier Y., Zala D., Gaillard M.C., Lefort N., Dufour N., Saudou F., Elalouf J.M., Hirsch E., Hantraye P., Deglon N., and Brouillet E. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated Huntingtin. Mol. Biol. Cell 17 (2006) 1652-1663
18. Bezprozvanny I., and Hayden M.R. Deranged neuronal calcium signaling and Huntington disease. Biochem. Biophys. Res. Commun. 322 (2004) 1310-1317
19. Birnstiel S., Gerber U., and Greene R.W. Adenosine-mediated synaptic inhibition: partial blockade by barium does not prevent anti-epileptiform activity. Synapse 11 (1992) 191-196
20. Blum D., Gall D., Galas M.C., D'Alcantara P., Bantubungi K., and Schiffmann S.N. The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. J. Neurosci. 22 (2002) 9122-9133
21. Blum D., Galas M.C., Gall D., Cuvelier L., and Schiffmann S.N. Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease. Neurobiol. Dis. 10 (2002) 410-426
22. Blum D., Hourez R., Galas M.C., Popoli P., and Schiffmann S.N. Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. Lancet Neurol. 2 (2003) 366-374
23. 2A antagonists. J. Neurosci. 23 (2003) 5361-5369
24. 2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes. Glia 43 (2003) 190-194
25. Brouillet E., Conde F., Beal M.F., and Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 59 (1999) 427-468
26. Brouillet E., Jacquard C., Bizat N., and Blum D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J. Neurochem. 95 (2005) 1521-1540
27. 2A-dopamine D2 receptor-receptor heteromerization. Qualitative and quantitative assessment by fluorescence and bioluminescence energy trasfer. J. Biol. Chem. 47 (2003) 46741-46749
28. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., and Morton A.J. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 19 (1999) 3248-3257
29. Cattaneo E., Zuccato C., and Tartari M. Normal Huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 6 (2005) 919-930
30. Cepeda C., Ariano M.A., Calvert C.R., Flores-Hernandez J., Chandler S.H., Leavitt B.R., Hayden M.R., and Levine M.S. NMDA receptor function in mouse models of Huntington disease. J. Neurosci. Res. 66 (2001) 525-539
31. Cepeda C., Hurst R.S., Calvert C.R., Hernandez-Echeagaray E., Nguyen O.K., Jocoy E., Christian L.J., Ariano M.A., and Levine M.S. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J. Neurosci. 23 (2003) 961-969
32. Cha J.H., Frey A.S., Alsdorf S.A., Kerner J.A., Kosinski C.M., Mangiarini L., Penney Jr. J.B., Davies S.W., Bates G.P., and Young A.B. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Phil. Trans. Roy. Soc. Lond. B: Biol. Sci. 354 (1999) 981-989
33. Chang D.T., Rintoul G.L., Pandipati S., and Reynolds I.J. Mutant Huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiol. Dis. 22 (2006) 388-400
34. Charvin D., Vanhoutte P., Pages C., Borrelli E., and Caboche J. Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 12218-12223
35. Chen J.F. The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment. Drug News Perspect. 16 (2003) 597-604
36. 2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci. 19 (1999) 9192-9200
37. 2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 21 (2001) RC143
38. 2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues. J. Biol. Chem. 280 (2005) 14331-14340
39. Choi D.W. Excitotoxic cell death. J. Neurobiol. 23 (1992) 1261-1276
40. Choi D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1 (1998) 623-630
41. Choo Y.S., Johnson G.V., MacDonald M., Detloff P.J., and Lesort M. Mutant Huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet. 13 (2004) 1407-1420
42. Chou S.Y., Lee Y.C., Chen H.M., Chiang M.C., Lai H.L., Chang H.H., Wu Y.C., Sun C.N., Chien C.L., Lin Y.S., Wang S.C., Tung Y.Y., Chang C., and Chern Y. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J. Neurochem. 93 (2005) 310-320
43. Coney A.M., and Marshall J.M. Role of adenosine and its receptors in the vasodilatation induced in the cerebral cortex of the rat by systemic hypoxia. J. Physiol. 509 (1998) 507-518
44. 2B receptor. Nature 407 (2000) 747-750
45. +-evoked glutamate release in vivo in young and aged rats. Neuroreport 10 (1999) 687-691
46. Corsi C., Melani A., Bianchi L., and Pedata F. Striatal A2A adenosine receptor antagonism differentially modifies striatal glutamate outflow in vivo in young and aged rats. Neuroreport 11 (2000) 2591-2595
47. Coyle J.T., and Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262 (1993) 689-695
48. 2A receptors. Naunyn. Schmied. Arch. Pharmacol. 353 (1996) 261-271
49. Danbolt N.C. Glutamate uptake. Prog. Neurobiol. 65 (2001) 1-105
50. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., and Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90 (1997) 537-548
51. 2A receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices. J. Neurosci. 24 (2004) 2905-2913
52. Dragatsis I., Dietrich P., and Zeitlin S. Expression of the Huntingtin-associated protein 1 gene in the developing and adult mouse. Neurosci. Lett. 282 (2000) 37-40
53. Duyao M.P., Auerbach A.B., Ryan A., Persichetti F., Barnes G.T., McNeil S.M., Ge P., Vonsattel J.P., Gusella J.F., Joyner A.L., et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 269 (1995) 407-410
54. Ferrante R.J., Kowall N.W., Cipolloni P.B., Storey E., and Beal M.F. Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization. Exp. Neurol. 119 (1993) 46-71
55. 2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 7238-7241
56. Ferré S., O'Connor W.T., Fuxe K., and Ungerstedt U. The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J. Neurosci. 13 (1993) 5402-5406
57. Ferré S., Fredholm B.B., Morelli M., Popoli P., and Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 20 (1997) 482-487
58. Ferré S., Popoli P., Gimenez-Llort L., Rimondini R., Muller C.E., Stromberg I., Ogren S.O., and Fuxe K. Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. Parkinsonism Relat. Disord. 7 (2001) 235-241
59. 2A-receptors. Glia 18 (1996) 152-160
60. 2A receptor attenuates 3-nitropropionic acid-induced striatal damage. J. Neurochem. 88 (2004) 538-544
61. Fredholm B.B., Ijzerman A.P., Jacobson K.A., Klotz K.N., and Linden J. International Union of Pharmacology XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53 (2001) 527-552
62. Fuxe K., and Ungerstedt U. Action of caffeine and theophyllamine on supersensitive dopamine receptors: considerable enhancement of receptor response to treatment with DOPA and dopamine receptor agonists. Med. Biol. 52 (1974) 48-54
63. Fuxe K., Stromberg I., Popoli P., Rimondini R., Torvinen M., Ogren S.O., Franco R., and Ferré S. Adenosina receptors and Parkinson's disease. Relevance of antagonistic adenosina and dopamine receptor interaction in the striatum. Adv. Neurol. 86 (2001) 345-353
64. 2 receptor antagonist, reduces cerebral ischemic injury in the mongolian gerbil. Life Sci. 55 (1994) PL61-PL65
65. Gauthier L.R., Charrin B.C., Borrell-Pages M., Dompierre J.P., Rangone H., Cordelieres F.P., De Mey J., MacDonald M.E., Lessmann V., Humbert S., and Saudou F. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118 (2004) 127-138
66. 2A receptors reduces transmitter outflow. Neurobiol. Dis. 17 (2004) 77-88
67. Grafton S.T., Mazziotta J.C., Pahl J.J., St George-Hyslop P., Haines J.L., Gusella J., Hoffman J.M., Baxter L.R., and Phelps M.E. A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease. Ann. Neurol. 28 (1990) 614-621
68. Greene J.G., and Greenamyre J.T. Bioenergetics and glutamate excitotoxicity. Prog. Neurobiol. 48 (1996) 613-634
69. Guidetti P., Luthi-Carter R.E., Augood S.J., and Schwarcz R. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol. Dis. 17 (2004) 455-461
70. Hayden M.R., Martin W.R., Stoessl A.J., Clark C., Hollenberg S., Adam M.J., Ammann W., Harrop R., Rogers J., and Ruth T. Positron emission tomography in the early diagnosis of Huntington's disease. Neurology 36 (1986) 888-894
71. 2A receptors suggests multiple cellular sites fro modulation of GABAergic neurons in rat striatum. J. Comp. Neurol. 431 (2001) 331-346
72. Hodgson J.G., Agopyran N., Gutekunst C.A., Leavitt B.R., LePiane F., Singaraja R., Smith D.J., Bissada N., McCutcheon K., Nasir J., Janot L., Li X.J., Stevens M.E., Rosemond E., Roder J.C., Phillips A.G., Rubin E.M., Hersch S.M., and Hayden M.R. A YAC mouse model for Huntington's disease with full-length mutant Huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23 (1999) 181-192
73. 2A) adenosine receptors antagonizes apoptosis due to serum deprivation in PC12 cells. J. Biol. Chem. 276 (2001) 13838-13846
74. 2A Receptors in Parkinson's Disease and Other CNS Disorders Meeting. Mass General Institute for Neurodegenerative Disease, Shriners Auditorium, Mass General Hospital, Boston, MA, USA, May 17-19 (2006)
75. Impagnatiello F., Bastia E., Ongini E., and Monopoli A. Adenosine receptors in neurological disorders. Emerg. Ther. Targets 4 (2000) 635-664
76. 11C]KF18446 PET in the rat brain after quinolinic acid lesion: comparison with the dopamine receptor imaging. Ann. Nucl. Med. 16 (2002) 467-475
77. Jacobson K.A., and Gao Z.-G. Adenosine receptors as therapeutics targets. Nat. Rev. Drug Discov. 5 (2006) 247-264
78. Jacobson K.A., von Lubitz D.K., Daly J.W., and Fredholm B.B. Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol. Sci. 17 (1996) 108-113
79. Jacobson K.A., Hoffmann C., Cattabeni F., and Abbracchio M.P. Adenosine-induced cell death: evidence for receptor-mediated signalling. Apoptosis 4 (1999) 197-211
80. Jarabek B.R., Yasuda R.P., and Wolfe B.B. Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. Brain 127 (2004) 505-516
81. Jeannateau F., and Chao M.V. Promoting neurotrophic effects by GPCR ligands. Novartis Found. Symp. 276 (2006) 181-189 (discussion 189-192, 233-237, 275-281)
82. Kuhl D.E., Phelps M.E., Markham C.H., Metter E.J., Riege W.H., and Winter J. Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. Ann. Neurol. 12 (1982) 425-434
83. 2A and dopamine D2 receptors in Chinese hamster ovary cells co-trasfected with the two receptors. Biochem. Pharmacol. 58 (1999) 1035-1045
84. olf in rat striatum. Mol. Pharmacol. 58 (2000) 771-777
85. Laforet G.A., Sapp E., Chase K., McIntyre C., Boyce F.M., Campbell M., Cadigan B.A., Warzecki L., Tagle D.A., Reddy P.H., Cepeda C., Calvert C.R., Jokel E.S., Klapstein G.J., Ariano M.A., Levine M.S., DiFiglia M., and Aronin N. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J. Neurosci. 21 (2001) 9112-9123
86. Latini S., and Pedata F. Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J. Neurochem. 79 (2001) 463-484
87. 2A receptor. Nature 388 (1997) 674-678
88. Lee F.S., and Chao M.V. Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 3555-3560
89. Levine M.S., Klapstein G.J., Koppel A., Gruen E., Cepeda C., Vargas M.E., Jokel E.S., Carpenter E.M., Zanjani H., Hurst R.S., Efstratiadis A., Zeitlin S., and Chesselet M.F. Enhanced sensitivity to N-methyl-d-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res. 58 (1999) 515-532
90. 2A adenosine receptors. Life Sci. 68 (2001) 1343-1350
91. Li L., Fan M., Icton C.D., Chen N., Leavitt B.R., Hayden M.R., Murphy T.H., and Raymond L.A. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. Neurobiol. Aging 24 (2003) 1113-1121
92. 2B adenosine receptors: radioligand binding, Western blotting, and coupling t5o Gq in human embryonic kidney 293 cells and HMC-1 mast cells. Mol. Pharmacol. 56 (1999) 705-713
93. Lipton S.A., and Rosenberg P.A. Excitatory amino acids as a final common pathway for neurologic disorders. New Engl. J. Med. 330 (1994) 613-622
94. Lodi R., Schapira A.H., Manners D., Styles P., Wood N.W., Taylor D.J., and Warner T.T. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann. Neurol. 48 (2000) 72-76
95. Maglione V., Cannella M., Martino T., De Blasi A., Frati L., and Squitieri F. The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion inHuntington's disease patients with predominant chorea. Neurosci. Lett. 393 (2006) 27-30
96. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., and Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996) 493-506
97. Marcoli M., Raiteri L., Bonfanti A., Monopoli A., Ongini E., Raiteri M., and Maura G. Sensitivity to selective adenosine A1 and A2A receptor antagonists of the release of glutamate induced by ischemia in rat cerebrocortical slices. Neuropharmacology 45 (2003) 201-210
98. 2A receptors in the mouse hippocampus. Abstract of the 8th International Symposium on Adenosine and Adenine Nucleotides. Ferrara, Italy, May 24-28 (2006)
99. 2A receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage. Ann. Neurol. 49 (2001) 727-735
100. Mazziotta J.C., Phelps M.E., Pahl J.J., Huang S.C., Baxter L.R., Riege W.H., Hoffman J.M., Kuhl D.E., Lanto A.B., and Wapenski J.A. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. New Engl. J. Med. 316 (1987) 357-362
101. 2A receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behaviour and ischemic brain damage induced by permanent focal ischemia in the rat. Brain Res. 959 (2003) 243-250
102. Mitchell I.J., Cooper A.J., and Griffiths M.R. The selective vulnerability of striatopallidal neurons. Prog. Neurobiol. 59 (1999) 691-719
103. 2A receptors results in neuroprotective effects in cerebral ischaemia in rats. Neuroreport 9 (1998) 3955-3959
104. 2A receptors: an overview. Brain Res. Rev. 31 (1999) 65-82
105. Morelli M. Adenosine A2A antagonists: potential preventive and palliative treatment for Parkinson's disease. Exp. Neurol. 184 (2003) 20-23
106. Morelli M., and Wardas J. Adenosine A(2a) receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's disease. Neurotoxicol. Res. 3 (2001) 545-556
107. 11C]SCH442416. Eur. J. Nucl. Med. Mol. Imag. 32 (2005) 405-413
108. Nasir J., Floresco S.B., O'Kusky J.R., Diewert V.M., Richman J.M., Zeisler J., Borowski A., Marth J.D., Phillips A.G., and Hayden M.R. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81 (1995) 811-823
109. 2A adenosine receptors. J. Pharmacol. Sci. 94 (2004) 100-102
110. 2A adenosine receptors. Glia 39 (2002) 133-147
111. Norenberg W., Wirkner K., and Illes P. Effect of adenosine and some of its structural analogues on the conductance of NMDA receptor channels in a subset of rat neostriatal neurones. Br. J. Pharmacol. 122 (1997) 71-80
112. Orlando L.R., Alsdorf S.A., Penney Jr. J.B., and Young A.B. The role of group I and group II metabotropic glutamate receptors in modulation of striatal NMDA and quinolinic acid toxicity. Exp. Neurol. 167 (2001) 196-204
113. 2A adenosine receptor antagonists. Mol. Pharmacol. 48 (1996) 970-974
114. Panov A.V., Gutekunst C.A., Leavitt B.R., Hayden M.R., Burke J.R., Strittmatter W.J., and Greenamyre J.T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 5 (2002) 731-736
115. Pavese N., Andrews T.C., Brooks D.J., Ho A.K., Rosser A.E., Barker R.A., Robbins T.W., Sahakian B.J., Dunnett S.B., and Piccini P. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain 126 (2003) 1127-1135
116. Pinna A., Wardas J., Simola N., and Morelli M. New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists. Life Sci. 77 (2005) 3259-3267
117. Pintor A., Quarta D., Pèzzola A., Reggio R., and Popoli P. SCH 58261 (an adenosine A(2A) receptor antagonist) reduces, only at low doses, K(+)-evoked glutamate release in the striatum. Eur. J. Pharmacol. 421 (2001) 177-180
118. 2A receptor antagonists prevent the increase in striatal glutamate levels induced by glutamate uptake inhibitors. J. Neurochem. 89 (2004) 152-156
119. Popoli P., Pèzzola A., Domenici M.R., Sagratella S., Diana G., Caporali M.G., Bronzetti E., Vega J., and de Carolis A.S. Behavioural and electrophysiological correlates of the quinolinic-acid model of Huntington's disease in rats. Brain Res. Bull. 35 (1994) 329-335
120. Popoli P., Pèzzola A., Reggio R., Caporali M.G., and de Carolis A.S. CGS 21680 antagonizes motor hyperactivity in a rat model of Huntington's disease. Eur. J. Pharmacol. 257 (1994) 5-6
121. 2a receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur. J. Pharmacol. 287 (1995) 215-217
122. 2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J. Neurosci. 22 (2002) 1967-1975
123. 2A receptor antagonists as neuroprotective agents. Curr. Med. Chem. Centr. Nerv. Sys. Agents 4 (2004) 35-45
124. 2A receptor antagonistm and neuroprotection: mechanisms, lights and shadows. Crit. Rev. Neurobiol. 16 (2004) 99-106
125. Porkka-Heiskanen T., Strecker R.E., Thakkar M., Bjorkum A.A., Greene R.W., and McCarley R.W. Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. Science 276 (1997) 59-67
126. 2A) receptors. Neurosci. Lett. 404 (2006) 143-147
127. 2A receptor protects sympathetic neurons against nerve growth factor withdrawal. J. Neurosci. Res. 77 (2004) 258-269
128. Reggio R., Pèzzola A., and Popoli P. The intrastriatal injection of an adenosina A(2) receptor antagonist prevents frontal cortex EEG abnormalities in a rat model of Huntington's disease. Brain Res. 831 (1999) 315-318
129. Ribeiro J.A., Sebastiao A.M., and de Mendonça A. Adenosine receptors in the nervous system: pathophysiological implications. Prog. Neurobiol. 68 (2003) 377-392
130. Rigamonti D., Bauer J.H., De-Fraja C., Conti L., Sipione S., Sciorati C., Clementi E., Hackam A., Hayden M.R., Li Y., Cooper J.K., Ross C.A., Govoni S., Vincenz C., and Cattaneo E. Wild type Huntingtin protects from apoptosis upstream of caspase-3. J. Neurosci. 20 (2000) 3705-3713
131. Robledo P., Ursu G., and Mahy N. Effects of adenosine and gamma-aminobutyric acid A receptor antagonists on N-methyl-d-aspartate induced neurotoxicity in the rat hippocampus. Hippocampus 9 (1999) 527-533
132. Roitberg B.Z., Emborg M.E., Sramek J.G., Palfi S., and Kordower J.H. Behavioral and morphological comparison of two non-human primate models of Huntington's disease. Neurosurgery 50 (2002) 137-145
133. 2A receptors in the rat central nervous system. J. Comp. Neurol. 401 (1998) 163-186
134. Saft C., Zange J., Andrich J., Muller K., Lindenberg K., Landwehrmeyer B., Vorgerd M., Kraus P.H., Przuntek H., and Schols L. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov. Disord. 20 (2005) 674-679
135. Saudou F., Finkbeiner S., Devys D., and Greenberg M.E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95 (1998) 55-66
136. Saura J., Angulo E., Ejarque A., Casado V., Tusell J.M., Moratalla R., Chen J.-F., Schwarschild M.A., Lluis C., Franco R., and Serratosa J. Adenosine a2A receptor stimulation potentiates nitric oxide release by activated microglia. J. Neurochem. 95 (2005) 919-929
137. Sawa A., Wiegand G.W., Cooper J., Margolis R.L., Sharp A.H., Lawler Jr. J.F., Greenamyre J.T., Snyder S.H., and Ross C.A. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat. Med. 5 (1999) 1194-1198
138. Schaffar G., Breuer P., Boteva R., Behrends C., Tzvetkov N., Strippel N., Sakahira H., Siegers K., Hayer-Hartl M., and Hartl F.U. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol. Cell 15 (2004) 95-105
139. Schiffmann S.N., Jacobs O., and Vanderhaeghen J.J. Striatal restricted adenosine A2 receptors (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J. Neurochem. 57 (1991) 1062-1067
140. 1 receptors are necessary for protection of the murine heart by remote, delayed adaptation to ischemia. Acta Physiol. Scand. 182 (2004) 133-143
141. Schulz P.E., Cook E.P., and Johnston D. Changes in paired-pulse facilitation suggest presynaptic involvement in long-term potentiation. J. Neurosci. 14 (1994) 5325-5337
142. Schwarzschild M.A., Chen J.F., and Ascherio A. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. Neurology 58 (2002) 1154-1160
143. Shin J.Y., Fang Z.H., Yu Z.X., Wang C.E., Li S.H., and Li X.J. Expression of mutant Huntingtin in glial cells contributes to neuronal excitotoxicity. J. Cell Biol. 171 (2005) 1001-1012
144. Stevens B., Porta S., Haak L.L., Gallo V., and Fields R.D. Adenosine: a neuron-glia transmitter promoting myelination in the CNS in response to action potentials. Neuron 36 (2002) 855-868
145. 2A adenosine receptor inhibits inflammation in a rat model of meningitis: synergy with the type IV phosphodiesterase inhibitor, rolipram. J. Infect. Dis. 180 (1999) 1550-1560
146. Sun Y., Savanenin A., Reddy P.H., and Liu Y.F. Polyglutamine-expanded Huntingtin promotes sensitization of N-methyl-d-aspartate receptors via post-synaptic density 95. J. Biol. Chem. 276 (2001) 24713-24718
147. Svenningsson P., Nomikos G.G., and Fredholm B.B. Biphasic changes in locomotor behavior and in expression of mRNA for NGF-1A and NGF-1B in rat striatum following acute caffeine administration. J. Neurosci. 15 (1995) 7612-7624
148. Svenningsson P., Fourreau L., Bloch B., Fredholm B.B., Gonon F., and Le Moine C. Opposite tonic modulation of dopamine and adenosine on c-fos mRNA expression in straitopallidal neurons. Neuroscience 89 (1999) 827-837
149. 2A receptors. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 1856-1860
150. 2A) receptor signaling in a mouse model of Huntington disease. Neurobiol. Dis. 23 (2006) 44-53
151. 1 adenosine receptors in the regulation of vascular tone. Am. J. Physiol. Heart Circ. Physiol. 288 (2005) H1411-H1416
152. 2A receptor blockade differentially influences excitotoxic mechanisms at pre- and post-synaptic sites in the rat striatum. J. Neurosci. Res. 77 (2004) 100-107
153. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
154. Trincavelli M.L., Marroni M., Tuscano D., Ceruti S., Mazzola A., Mitro N., Abbracchio M.P., and Martini C. Regulation of A2B adenosine receptor functioning by tumour necrosis factor a in human astroglial cells. J. Neurochem. 91 (2004) 1180-1190
155. Turmaine M., Raza A., Mahal A., Mangiarini L., Bates G.P., and Davies S.W. Non-apoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 8093-8097
156. van Calker D., Muller M., and Hamprecht B. Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J. Neurochem. 33 (1979) 999-1005
157. 2A receptor signaling in striatal cells expressing mutant Huntingtin. FASEB J. 15 (2001) 1245-1247
158. 2A receptor function in peripheral blood cells in Huntington's disease. FASEB J. 17 (2003) 2148-2150
159. von Lubitz D.K.J.E. Adenosine and cerebral ischemia: therapeutic future or death of a brave concept?. Eur. J. Pharmacol. 371 (1999) 85-102
160. 3 receptor stimulation and cerebral ischemia. Eur. J. Pharmacol. 263 (1994) 59-67
161. von Lubitz D.K.J.E., Beenhakker M., Lin R.C., Carter M.F., Paul I.A., Bischofberger N., and Jacobson K.A. Reduction of post-ischemic brain damage and memory deficits following treatment with the selective adenosine A1 receptor agonist. Eur. J. Pharmacol. 302 (1996) 43-48
162. Wanker E.E., Rovira C., Scherzinger E., Hasenbank R., Walter S., Tait D., Colicelli J., and Lehrach H. HIP-I: a Huntingtin interacting protein isolated by the yeast two-hybrid system. Hum. Mol. Genet. 6 (1997) 487-495
163. Wellington C.L., Ellerby L.M., Hackam A.S., Margolis R.L., Trifiro M.A., Singaraja R., McCutcheon K., Salvesen G.S., Propp S.S., Bromm M., Rowland K.J., Zhang T., Rasper D., Roy S., Thornberry N., Pinsky L., Kakizuka A., Ross C.A., Nicholson D.W., Bredesen D.E., and Hayden M.R. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem. 273 (1998) 9158-9167
164. Wellington C.L., Leavitt B.R., and Hayden M.R. Huntington disease: new insights on the role of Huntingtin cleavage. J. Neural Transm. Suppl. 58 (2000) 1-17
165. Wirkner K., Assmann H., Koles L., Gerevich Z., Franke H., Norenberg W., Boehm R., and Illes P. Inhibition by adenosine A(2A) receptors of NMDA but not AMPA currents in rat neostriatal neurons. Br. J. Pharmacol. 130 (2000) 259-269
166. Yin H.H., and Knowlton B.J. The role of the basal ganglia in habit formation. Nat. Rev. Neurosci. 7 (2006) 464-476
167. 2A receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury. Nat. Med. 10 (2004) 1081-1087
168. 2A receptors modulate psychomotor activity and brain injury by distinct cellular mechanisms. Purinergic Signaling 2, 58. Abstract of the 8th International Symposium on Adenosine and Adenine Nucleotides. Ferrara, Italy, May 24-28 (2006)
169. Zeitlin S., Liu J.P., Chapman D.L., Papaioannou V.E., and Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat. Genet. 11 (1995) 155-163
170. Zeron M.M., Hansson O., Chen N., Wellington C.L., Leavitt B.R., Brundin P., Hayden M.R., and Raymond L.A. Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33 (2002) 849-860
171. 3 adenosine receptor. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 7432-7436
172. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., MacDonald M.E., Friedlander R.M., Silani V., Hayden M.R., Timmusk T., Sipione S., and Cattaneo E. Loss of Huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293 (2001) 493-498
173. Zuccato C., Tartari M., Crotti A., Goffredo D., Valenza M., Conti L., Cataudella T., Leavitt B.R., Hayden M.R., Timmusk T., Rigamonti D., and Cattaneo E. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 35 (2003) 76-83